Cardiac Amyloidosis: Emerging Diagnostic and Treatment Approaches

Published: 08 February 2024

  • Views:

    Views Icon 102
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

This micro-learning series focuses on the forefront of cardiac amyloidosis, a rapidly advancing field in healthcare. Providing a focussed and tailored update for key healthcare practitioners seeking to enhance their understanding of the latest developments in the diagnosis and treatment of cardiac amyloidosis and its consequences. Throughout this series, esteemed faculty delve into the intricate nature of amyloidosis, offering insights into the evolving management practices in cardiac amyloidosis. This educational journey navigates the nuances of diagnosing cardiac amyloidosis, emphasising the ability to distinguish between various types of the disease, addressing common pitfalls in assessment and underscoring the importance of a collaborative interdisciplinary approach.

 

 

 

Discover New Horizons in Amyloidosis (NHA)

Curious about the latest advancements in diagnosing and treating cardiac amyloidosis? Join us for New Horizons in Amyloidosis (NHA), a virtual conference on February 28, 2024. Designed to educate healthcare professionals, this event will cover evolving management practices tailored to update and inform a diverse range of HCPs.

 

This programme is supported by an unrestricted educational grant from AstraZeneca.

Learning Objectives

  • Understand the nature of amyloidosis and its effects on various organs, particularly the heart
  • Distinguish between light-chain (AL) amyloidosis, wild type TTR amyloidosis and hereditary TTR amyloidosis in terms of their clinical manifestations and their different treatments
  • Recognise the novel challenges of managing heart failure in cardiac amyloidosis, including both medical management and the role of devices
  • Understand the critically important interaction between haematologists and cardiologists in the therapy of AL amyloidosis
  • Develop an understanding of novel therapies currently in clinical trials of TTR and AL amyloidosis
  • Identify their own roles and responsibilities in the management TTR and AL amyloidosis as part of a multidisciplinary team

Target Audience

  • Cardiologists
  • Imaging Specialists
  • Electrophysiologists
  • Primary care practitioners
  • Haematologists
  • Cardiac Nurse Practitioners

More from this programme

Part 1

An Overview of Amyloidosis:

In this video, Prof Philip Hawkins (University College London, London, UK), addresses some important key questions surrounding amyloidosis, a complex condition characterised by the abnormal accumulation of amyloid protein in tissues. He explores the nature of amyloid and the definition of amyloidosis, discussing its various forms and the significance of distinguishing among them. Join him as he unravels the importance of understanding the cardiac and non-cardiac manifestations of amyloidosis in clinical practice.

About the episode

In this video, Prof Philip Hawkins (University College London, London, UK), addresses some important key questions surrounding amyloidosis, a complex condition characterised by the abnormal accumulation of amyloid protein in tissues. He explores the nature of amyloid and the definition of amyloidosis, discussing its various forms and the significance of distinguishing among them. Join him as he unravels the importance of understanding the cardiac and non-cardiac manifestations of amyloidosis in clinical practice.

Faculty Biographies

Philip Hawkins

Philip Hawkins

Professor of Medicine and Clinical Director

Prof Philip Hawkins is a Professor of Medicine at University College London and Clinical Director of the NHS National Amyloidosis Centre at The Royal Free, London, UK. He is a rheumatologist and clinical scientist renowned for his studies on amyloidosis. His seminal work includes development and implementation of serum amyloid P component (SAP) scintigraphy for diagnosis and quantification of systemic amyloidosis.

Prof Hawkin’s clinical research programme is focused on diagnosis, pathogenesis, monitoring and treatment of amyloidosis and inherited autoinflammatory diseases with an emphasis on translational, early phase and otherwise novel approaches. He has a particular interest in the development of new imaging methods.

View full profile

Comments

You must be to comment. If you are not registered, you can register here.